|Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials|
N Sattar, D Preiss, HM Murray, P Welsh, BM Buckley, AJM de Craen, ...
The Lancet 375 (9716), 735-742, 2010
|Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials|
KK Ray, SRK Seshasai, S Wijesuriya, R Sivakumaran, S Nethercott, ...
The Lancet 373 (9677), 1765-1772, 2009
|Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis|
D Preiss, SRK Seshasai, P Welsh, SA Murphy, JE Ho, DD Waters, ...
Jama 305 (24), 2556-2564, 2011
|Interpretation of the evidence for the efficacy and safety of statin therapy|
R Collins, C Reith, J Emberson, J Armitage, C Baigent, L Blackwell, ...
The Lancet 388 (10059), 2532-2561, 2016
|Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials|
SL Kristensen, R RÝrth, PS Jhund, KF Docherty, N Sattar, D Preiss, ...
The lancet Diabetes & endocrinology 7 (10), 776-785, 2019
|HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials|
DI Swerdlow, D Preiss, KB Kuchenbaecker, MV Holmes, JEL Engmann, ...
The Lancet 385 (9965), 351-361, 2015
|Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials|
J Armitage, C Baigent, E Barnes, DJ Betteridge, L Blackwell, M Blazing, ...
The Lancet 393 (10170), 407-415, 2019
|Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial|
SE Nissen, E Stroes, RE Dent-Acosta, RS Rosenson, SJ Lehman, ...
Jama 315 (15), 1580-1590, 2016
|Statin safety and associated adverse events: a scientific statement from the American Heart Association|
CB Newman, D Preiss, JA Tobert, TA Jacobson, RL Page, LB Goldstein, ...
Arteriosclerosis, thrombosis, and vascular biology 39 (2), e38-e81, 2019
|Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations|
D Preiss, N Sattar
Clinical science 115 (5), 141-150, 2008
|Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data|
N Ghouri, D Preiss, N Sattar
Hepatology 52 (3), 1156-1161, 2010
|PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study|
AF Schmidt, DI Swerdlow, MV Holmes, RS Patel, Z Fairhurst-Hunter, ...
The lancet Diabetes & endocrinology 5 (2), 97-105, 2017
|Non-alcoholic fatty liver disease|
N Sattar, E Forrest, D Preiss
Bmj 349, 2014
|Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine†…|
SL Kristensen, D Preiss, PS Jhund, I Squire, JS Cardoso, B Merkely, ...
Circulation: Heart Failure 9 (1), e002560, 2016
|SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?|
N Sattar, J McLaren, SL Kristensen, D Preiss, JJ McMurray
Diabetologia 59, 1333-1339, 2016
|GDF15 mediates the effects of metformin on body weight and energy balance|
AP Coll, M Chen, P Taskar, D Rimmington, S Patel, JA Tadross, I Cimino, ...
Nature 578 (7795), 444-448, 2020
|Association of lipid fractions with risks for coronary artery disease and diabetes|
J White, DI Swerdlow, D Preiss, Z Fairhurst-Hunter, BJ Keating, ...
JAMA cardiology 1 (6), 692-699, 2016
|The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study|
WG Herrington, D Preiss, R Haynes, M von Eynatten, N Staplin, ...
Clinical kidney journal 11 (6), 749-761, 2018
|Lipid-modifying therapies and risk of pancreatitis: a meta-analysis|
D Preiss, MJ Tikkanen, P Welsh, I Ford, LC Lovato, MB Elam, JC LaRosa, ...
Jama 308 (8), 804-811, 2012
|Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies|
AK Loomis, S Kabadi, D Preiss, C Hyde, V Bonato, M St. Louis, J Desai, ...
The Journal of Clinical Endocrinology & Metabolism 101 (3), 945-952, 2016